What is Halozyme Therapeutics Inc. Quarterly Revenue?

Halozyme Therapeutics Inc. Quarterly Revenue Halozyme Therapeutics Inc Jun-2026 Quarterly Revenue is $481 Million which is growth of 47.7% YoY.

What is Halozyme Therapeutics Inc. Quarterly Net Profit?

Halozyme Therapeutics Inc. Quarterly Net Profit Halozyme Therapeutics Inc Jun-2026 Quarterly Net Profit is $230 Million which is growth of 39.2% YoY.

What is Halozyme Therapeutics Inc. Annual Revenue?

Halozyme Therapeutics Inc. Annual Revenue Halozyme Therapeutics Inc Dec-2025 Annual Revenue is $1,397 Million which is growth of 37.6% YoY.

What is Halozyme Therapeutics Inc. Annual Net Profit?

Halozyme Therapeutics Inc. Annual Net Profit Halozyme Therapeutics Inc Dec-2025 Annual Net Profit is $317 Million which is growth of -28.6% YoY.

What is Halozyme Therapeutics Inc. Total Shareholders Fund?

Halozyme Therapeutics Inc. Total Shareholders Fund Halozyme Therapeutics Inc Dec-2025 Total Shareholders Fund is $49 Million which is growth of -86.6% YoY.

What is Halozyme Therapeutics Inc. Total Assets?

Halozyme Therapeutics Inc. Total Assets Halozyme Therapeutics Inc Dec-2025 Total Assets is $2,525 Million which is growth of 22.4% YoY.

What is Halozyme Therapeutics Inc. Book Value Per Share?

Halozyme Therapeutics Inc. Book Value Per Share Halozyme Therapeutics Inc Book Value Per Share is $1 which is growth of -57.2% YoY.

What is Halozyme Therapeutics Inc. ROE?

Halozyme Therapeutics Inc. ROE Halozyme Therapeutics Inc ROE is 0% which is growth of 0% YoY.

What is Halozyme Therapeutics Inc. Cash From Operating Activity?

Halozyme Therapeutics Inc. Cash From Operating Activity Halozyme Therapeutics Inc Dec-2025 Cash From Operating Activity is $652 Million which is growth of 36.0% YoY.

What is Halozyme Therapeutics Inc. Net Cash Flow?

Halozyme Therapeutics Inc. Net Cash Flow Halozyme Therapeutics Inc Dec-2025 Net Cash Flow is $21 Million which is growth of 916.3% YoY.

Halozyme Therapeutics Inc.

XNAS: HALO

Turnaround Potential

Download real time

0.58(0.53%)

80.37% Gain from 52W Low

1.8M

XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Halozyme Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Halozyme Therapeutics Inc share price target, revenues, EPS, net income and more

Halozyme Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Halozyme Therapeutics Inc Jun-2026 Quarterly Revenue is $481 Million which is growth of 47.7% YoY.
POSITIVE
Quarterly Net Profit Halozyme Therapeutics Inc Jun-2026 Quarterly Net Profit is $230 Million which is growth of 39.2% YoY.

Halozyme Therapeutics Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	481	376.7	451.8	354.3	325.7	264.9	298	290.1	231.4	195.9	230	216	221
CostOfRevenue_Q Cost Of Rev.	79.2	79.2	78.8	55.2	46.4	48.4	42.1	49.4	39.6	28.3	52.3	54.8	50.1
GrossProfit_Q Gross Profit	401.8	297.5	373	299	279.4	216.5	256	240.7	191.8	167.6	177.7	161.2	171
OEXPNS_Q Operating Exp. ⌄	114.2	113	132.3	81.1	76.9	74.9	80.5	77.5	74.5	72	76.7	72.9	76.5
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	57	57.9	77	46.1	41.6	42.4	42.3	41.2	35.7	35.1	37.6	35.3	39
ResearchAndDevlopmentExpenses_Q RnD Exp.	27.7	25.6	31.9	17.3	17.5	14.8	20.4	18.5	21	19.1	21.3	17.3	19.7
OP_Q Operating Profit	287.7	184.5	240.7	217.9	202.4	141.5	175.5	163.2	117.2	95.5	101	88.3	94.5
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-5.6	-5.5	-4.9	-4.3	-4.4	-4.5	-4.5	-4.5	-4.5	-4.5	-5.2	-4.5	-4.5
Others_Q Other Interest Earned	-	-	-	-	-	-	-	-	-	-	-	-	-
IntExpNonOperating_Q Interest Exp. Non Operating	5.6	5.5	4.9	4.3	4.4	4.5	4.5	4.5	4.5	4.5	5.2	4.5	4.5
PBT_Q Profit Before Tax	284.9	180.3	-100.9	219	204.9	143.8	178.2	165.2	117.7	96	101.2	101.8	93.2
TAX_Q Tax	55	30.3	40.7	43.7	39.8	25.7	41.2	28.1	24.5	19.2	15.8	19.9	18.4
NICommonStockholders_Q Net Income Common Stockholders ⌄	229.9	150.1	-141.6	175.2	165.2	118.1	137	137	93.3	76.8	85.4	81.8	74.8
NP_Q Net Profit	229.9	150.1	-141.6	175.2	165.2	118.1	137	137	93.2	76.8	85.4	81.8	74.8
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	229.9	150.1	-141.6	175.2	165.2	118.1	137	137	93.3	76.8	85.4	81.8	74.8
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	229.9	150.1	-141.6	175.2	165.2	118.1	137	137	93.3	76.8	85.4	81.8	74.8
EPS_Q Basic EPS	2	1.3	-1.2	1.5	1.4	1	1.1	1.1	0.7	0.6	0.7	0.6	0.6
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	1.9	1.2	0.9	1.4	1.3	0.9	1	1	0.7	0.6	0.6	0.5	0.5
SHARE_Q Number Of Shares End	117.3	118.1	117.7	117.2	121.3	123.2	126.4	126.9	127.1	126.9	129	132	131.7
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	229.9	150.1	-141.6	175.2	165.2	118.1	137	137	93.3	76.8	85.4	81.8	74.8
NormalizedIncome_Q Normalized Income	227.6	149	109	171	159.6	112.5	131.4	131.6	89.2	72.8	80.9	67.4	72.2
InterestIncome_Q Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-
INT_Q Interest	5.6	5.5	4.9	4.3	4.4	4.5	4.5	4.5	4.5	4.5	5.2	4.5	4.5
NetInterestIncome_Q Net Interest Income	-5.6	-5.5	-4.9	-4.3	-4.4	-4.5	-4.5	-4.5	-4.5	-4.5	-5.2	-4.5	-4.5
EBIT_Q EBIT	290.5	185.8	-95.9	223.3	209.3	148.4	182.8	169.7	122.3	100.5	106.4	106.3	97.7
EBITDA_Q EBITDA	324.5	219.6	-69.3	243.7	229.8	168.8	203.2	190	142.6	120.7	127.1	129.3	118.3
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	74.7	75	75.5	52.6	43.6	45.7	39.4	46.8	37	25.9	49.4	52.1	47.3
ReconciledDepreciation_Q Reconciled Depr.	34	33.7	26.7	20.4	20.5	20.5	20.4	20.4	20.3	20.2	20.7	23.1	20.6
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	229.9	150.1	-141.6	175.2	165.2	118.1	137	137	93.3	76.8	85.4	81.8	74.8
NormalizedEBITDA_Q Normalized EBITDA	321.6	218.3	267.4	238.3	222.9	162	195.9	183.6	137.6	115.8	121.7	111.4	115.1

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Halozyme Therapeutics Inc competitor comparison and performance snapshot within industry

Halozyme Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Halozyme Therapeutics Inc Dec-2025 Annual Revenue is $1,397 Million which is growth of 37.6% YoY.
NEGATIVE
Annual Net Profit Halozyme Therapeutics Inc Dec-2025 Annual Net Profit is $317 Million which is growth of -28.6% YoY.

Halozyme Therapeutics Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	28.4%	39.2%		1,396.6	1,015.3	829.3	660.1	443.3	267.6	196	151.9	316.6	146.7	135.1
TotalOperatingRevenues_A Operating Rev. Ann.	28.4%	39.2%	1,663.7	1,396.6	1,015.3	829.3	660.1	443.3	267.6	196	151.9	316.6	146.7	135.1
CostOfRevenue_A Cost Of Rev. Ann.	18%	39.4%	292.4	228.8	159.4	192.4	139.3	81.4	43.4	45.6	10.1	31.2	33.2	29.3
GrossProfit_A Gross Profit Ann.	30.9%	39.1%	1,371.3	1,167.8	855.9	636.9	520.8	361.9	224.2	150.5	141.7	285.5	113.5	105.8
OEXPNS_A Operating Exp. Ann.	13%	35.5%	440.5	365.2	304.4	299.3	253.3	86	80	218.1	211.1	204.5	196.7	133.3
OP_A Operating Profit Ann.	44.2%	40.9%	930.8	802.6	551.5	337.6	267.5	275.9	144.3	-67.6	-69.3	81	-83.2	-27.5
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-	-20.3	-18.1	-18.1	-18.8	-17	-7.5	-20.4	-11.6	-18	-22	-20	-5.2
Others_A Other Interest Earned Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
IntExpNonOperating_A Interest Exp. Non Operating Ann.	2.1%	-2.4%	20.3	18.1	18.1	18.8	17	7.5	20.4	11.6	18	22	20	5.2
OtherExpenses_A Other Exp. Ann.	-	-		-317.6	23.8	29.5	-1.7	-19.9	5.4	7	7.6	2.6	1.3	0.4
PBT_A PBT Ann.	23.3%	29.3%	583.3	466.9	557.1	348.3	248.9	248.5	129.3	-72.3	-79.8	61.6	-101.9	-32.2
TAX_A Tax Ann.	47.4%	275.8%	169.7	150	113	66.7	46.8	-154.2	0.2	-0	0.5	-1.4	1.2	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	16.2%	19.7%	413.6	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
NP_A Net Profit Ann.	16.2%	19.7%	413.6	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	16.2%	19.7%	413.6	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	16.2%	19.7%	413.6	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
EPS_A EPS Ann.	20.1%	21.1%		2.6	3.5	2.1	1.5	2.9	1	-0.5	-0.6	0.5	-0.8	-0.3
DilutedEPS_A Diluted EPS Ann.	22.9%	23.6%		2.6	3.4	2.1	1.4	2.7	0.9	-0.5	-0.6	0.5	-0.8	-0.3
SHARE_Q Number Of Shares End	-4.5%	-2.7%		117.7	126.4	129	135.3	140.1	135.1	141	144.2	141.8	128.2	128.4
TotalExpenses_A Total Exp. Ann.	14.8%	37%		594	463.9	491.7	392.6	167.4	123.3	263.6	221.2	235.6	229.9	162.5
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	16.2%	19.7%	413.6	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
NormalizedIncome_A Normalized Income Ann.	37.8%	33.9%	656.5	532.4	425.2	257.7	203.5	417.2	123.7	-79.2	-85.9	61.4	-103.8	-32.7
InterestIncome_A Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
INT_A Interest Ann.	2.1%	-2.4%	20.3	18.1	18.1	18.8	17	7.5	20.4	11.6	18	22	20	5.2
EBITDA_A EBITDA Ann.	22%	30.2%	718.4	573.1	656.5	452	315.5	259	153	-56.6	-59.4	85.8	-79.5	-25.4
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	17.9%	38%	277.8	217.4	149.2	181.3	132.8	81.4	43.4	45.6	10.1	31.2	33.2	29.3
ReconciledDepreciation_A Reconciled Depr. Ann.	21.1%	92.9%	114.8	88.1	81.3	84.9	49.6	3	3.3	4.1	2.4	2.2	2.4	1.7
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	16.2%	19.7%	413.6	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
NormalizedEBITDA_A Normalized EBITDA Ann.	41.1%	43.3%	1,045.6	890.6	632.8	422.4	317.2	278.9	147.5	-63.5	-66.9	83.2	-80.8	-25.8

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

37.6%

2Y CAGR

29.8%

3Y CAGR

28.4%

5Y CAGR

39.2%

7Y CAGR

37.3%

10Y CAGR

26.3%

Total Revenue Annual growth is stable compared to historical averages.

Net Profit Ann.

1Y CHG

-28.6%

2Y CAGR

6.1%

3Y CAGR

16.2%

5Y CAGR

19.7%

Net Profit Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

20%

2Y CAGR

10.5%

3Y CAGR

13%

5Y CAGR

35.5%

7Y CAGR

8.1%

10Y CAGR

10.6%

Operating Expenses Annual Cr growth is stable compared to historical averages.

Halozyme Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Total Shareholders Fund Halozyme Therapeutics Inc Dec-2025 Total Shareholders Fund is $49 Million which is growth of -86.6% YoY.
POSITIVE
Total Assets Halozyme Therapeutics Inc Dec-2025 Total Assets is $2,525 Million which is growth of 22.4% YoY.

Halozyme Therapeutics Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	11.1%	34.2%	2,525.3	2,063.5	1,733.3	1,841.5	1,104.4	579.9	565.9	440.3	519.9	261.5	181.8
CA_A Total Current Assets Ann.	3.7%	8.3%	825.2	1,085.3	746.4	739	926.3	554.8	543.4	427.9	510.4	256.5	171.8
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	-26.7%	-17.2%	142.8	596.1	336	362.8	740.9	368	421.3	354.5	469.2	205	108.3
Receivables_A Change In Account Receivables Ann.	24.1%	35.2%	441.3	308.5	234.2	231.1	91	97.7	59.4	30	22.1	15.7	32.4
Inventories_A Inventories Ann.	20.8%	23.8%	176.5	141.9	127.6	100.1	53.9	60.8	29.4	22.6	5.2	14.6	9.5
OtherCurrentAssets_A Other Current Assets Ann.	12.8%	17.9%	64.6	39	48.6	45	40.5	28.3	33.4	20.7	13.9	21.3	21.5
TotalNonCurrentAssets_A Total Non Current Assets Ann.	15.5%	132.2%	1,700.1	978.1	986.9	1,102.5	178.1	25.2	22.4	12.4	9.6	5	10
NetPPE_A Net PPE Ann.	2.8%	50.6%	82.1	75	74.9	75.6	8.8	10.6	10.9	7.5	3.5	4.3	3.9
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	28%	30.9%	56.2	80.6	17.8	26.8	13.9	14.6	11.6	4.9	6.1	0.7	6.1
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	14%	42%	2,476.5	1,699.7	1,649.5	1,671.7	907.5	428.9	474.1	191.4	311.6	294	138.8
CL_A Total Current Liabilities Ann.	10.6%	-15.9%	177.1	139.1	112.5	130.8	117.2	421.4	85.6	149.4	131.3	54.6	62.5
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	15.7%	51.2%	177.1	139.1	112.5	114.2	26	22.4	62.1	53.6	47.6	32.4	31.3
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-	-	-	-	-	13.3	89.4	397.2	19.5	91.5	77.2	17.4	21.9
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-	-	3.3	1.8	1.8	4	4.3	6.6	4.8	9.3
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	14.3%	214.3%	2,299.4	1,560.6	1,537	1,540.9	790.3	7.5	388.5	42	180.3	239.4	76.3
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	12.8%	-	2,142.6	1,505.8	1,499.3	1,492.8	787.3	-	383.1	34.9	125.1	199.2	28
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	-34%	-20.2%	48.8	363.8	83.8	169.8	197	151.1	91.8	248.9	208.4	-32.5	43
EQCAP_A Equity Share Capital Ann.	-34%	-20.2%	48.8	363.8	83.8	169.8	197	151.1	91.8	248.9	208.4	-32.5	43
CapitalStock_A Capital Stock Ann.	0%	0%	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
RetainedEarnings_A Retained Earnings Ann.	-27.4%	-	54.8	359.9	90.6	143.2	-58.9	-474.6	-603.7	-531.4	-522.4	-585.3	-482.7
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	-18.1	3.8	-9.3	-0.9	-0.6	0	0.2	-0.3	-0.5	-0	-0.1
TotalCapitalization_A Total Capitalization Ann.	9.6%	70.7%	2,191.4	1,869.6	1,583.1	1,662.6	984.2	151.1	474.8	283.8	333.5	166.8	71
TangibleAssets_A Tangible Assets Ann.	-	-	-1,513	-454.8	-805.9	-785.9	197	151.1	91.8	248.9	208.4	-32.5	43
WC_A Working Capital Ann.	2.1%	37.2%	648.1	946.2	633.9	608.2	809.1	133.4	457.8	278.5	379	202	109.3
InvestedCapital_A Invested Capital Ann.	9.4%	31.9%	2,191.4	1,869.6	1,583.1	1,675.9	1,073.6	548.3	494.4	375.3	410.7	184.1	92.8
TangibleBookValue_A Tangible Book Value Ann.	-	-	-1,513	-454.8	-805.9	-785.9	197	151.1	91.8	248.9	208.4	-32.5	43
Borrowings_A Borrowings Ann.	12.5%	40.1%	2,142.6	1,505.8	1,499.3	1,506.1	876.7	397.2	402.6	126.4	202.4	216.6	49.8
NetDebt_A Net Debt Ann.	16.5%	51.8%	2,008.8	1,390	1,380.9	1,271.9	758	249.5	282.4	68.4	33.6	149.9	6.5
ShareIssued_A Share Issued Ann.	-4.5%	-2.7%	117.8	123.1	126.8	135.2	137.5	135	136.7	144.7	142.8	129.5	128.2
SHARE_Q Number Of Shares End	-4.5%	-2.7%	117.7	126.4	129	135.3	140.1	135.1	141	144.2	141.8	128.2	128.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

22.4%

2Y CAGR

20.7%

3Y CAGR

11.1%

5Y CAGR

34.2%

7Y CAGR

28.3%

10Y CAGR

30.1%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

27.3%

2Y CAGR

25.5%

3Y CAGR

10.6%

5Y CAGR

-15.9%

7Y CAGR

2.5%

10Y CAGR

11%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

-86.6%

2Y CAGR

-23.7%

3Y CAGR

-34%

5Y CAGR

-20.2%

7Y CAGR

-20.8%

10Y CAGR

1.3%

Total ShareHolders Funds Annual is falling faster than historical averages.

Halozyme Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share Halozyme Therapeutics Inc Book Value Per Share is $1 which is growth of -57.2% YoY.
NEUTRAL
ROE Halozyme Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Halozyme Therapeutics Inc., Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	23.39%	15.75%	13.72%	47.82%	22.53%	-14.36%	-16.73%	16.12%	-46.48%	-18.54%
ROE_A ROE Ann. %	-	-	-	198.42%	222.07%	110.23%	231.44%	106.33%	-42.41%	-35.14%	71.60%	-1,958.98%	-76.42%
ROIC_Q ROIC %	-	-	-	7.3	5.4	3.8	6.1	15	-7.6	0.2	36.9	-	5.9
OPMPCT_A OPM Ann. %	12.3%	1.3%	57.47%	54.32%	40.71%	40.53%	62.24%	53.91%	-34.50%	-45.65%	25.58%	-56.72%	-20.33%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	1.2	1.7	1.8	1.4	1	1.8	0.7	3.2	2.8	3.7
ASETTO_A Asset Turnover Ann. %	-	-	-	0.5	0.5	0.5	0.5	0.5	0.4	0.3	0.8	0.7	0.8
WCTO_A Working Capital Turnover Ann.	26%	1.9%	2.2	1.1	1.3	1.1	0.6	2	0.4	0.6	0.8	0.7	1.2
QuickRatio_A Quick Ratio Ann.	-	-	-	6.5	5.1	4.5	7.1	1.1	5.6	2.6	3.7	4	2.3
CRATIO_A Current Ratio Ann.	-	-	-	7.8	6.6	5.7	7.9	1.3	6.4	2.9	3.9	4.7	2.8
IC_A Interest Coverage Ratio Ann.	-	-	-	31.8	19.6	15.7	34	7.4	-5.2	-3.4	3.8	-4.1	-5.2
LTDE_A LT Debt To Equity Ann.	-	-	-	4.1	17.9	8.8	4	-	4.2	0.1	0.6	-	0.7

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Halozyme Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Halozyme Therapeutics Inc Dec-2025 Cash From Operating Activity is $652 Million which is growth of 36.0% YoY.
POSITIVE
Net Cash Flow Halozyme Therapeutics Inc Dec-2025 Net Cash Flow is $21 Million which is growth of 916.3% YoY.

Halozyme Therapeutics Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	39.5%	63.7%	651.6	479.1	388.6	240.1	299.4	55.5	-85.4	-49.5	134.1	-50.4	-37.1
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	16.2%	19.7%	316.9	444.1	281.6	202.1	402.7	129.1	-72.2	-80.3	63	-103	-32.2
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	21.1%	92.9%	88.1	81.3	84.9	49.6	3	3.3	4.1	2.4	2.2	2.4	1.7
DepreciationAndAmortization_A Depreciation And Amortization Ann.	21.1%	92.9%	88.1	81.3	84.9	49.6	3	3.3	4.1	2.4	2.2	2.4	1.7
DeferredTax_A Deferred Tax Ann.	-75.3%	-	0.6	0.5	34.5	40	-155.4	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-75.3%	-	0.6	0.5	34.5	40	-155.4	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	28.4%	24.6%	51.6	43.4	36.6	24.4	20.8	17.2	34.8	35.7	30.7	25.6	20.8
OtherNonCashItems_A Other Non Cash Items Ann.	251.2%	85.5%	298.8	8.4	-4.6	6.9	22.4	13.6	-2	1.7	17.8	7.1	1.2
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-152.3	-89.3	-38.7	-86	3.7	-108.4	-50.5	-5.9	20.7	17	-29.5
ChangeInReceivables_A Change In Receivables Ann.	-	-	-128.1	-74.3	-3.3	-83.9	6.8	-38.3	-29.4	11.6	-6.5	16.7	-23.3
ChangeInInventory_A Change In Inventory Ann.	-	-	2.6	-67.4	-26.9	-17.5	7.4	-31.4	-6.7	-17.5	9.5	-5.1	-3.1
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-36.7%	-	6.2	47	-12.6	24.5	1.2	-41.2	4.6	5.7	15.6	-0.2	13.9
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-1.3
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-545.8	-262.7	-96.9	-487	-406.3	78.4	-5.6	2.5	-163.7	-76.8	5.9
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-7	-10.7	-15.3	-4.8	-1.5	-1.4	-4	-4.7	-1.4	-3.1	-2.4
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-7	-10.7	-15.3	-4.8	-1.5	-2.5	-4	-4.7	-1.4	-3.1	-2.4
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-726			-999.1	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-726			-999.1	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-247.4	-647.6	-292.9	-255.2	-652.5	-226.2	-389.8	-311.1	-398.2	-155.4	-71.5
SaleOfInvestment_A Sale Of Investment Ann.	-1.1%	18.7%	722.3	395.6	211.3	746.1	247.7	306	388.3	318.3	235.8	81.8	79.7
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	26	-	-	-	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	-	-	-85.2	-218.9	-408	362.4	77.9	-106.3	153.2	-63.8	131.7	150.6	13.1
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-10.3%	-	451.1		-13.5	624.6	415.8	-19.6	339.3	-77.5	-16	148.8
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-10.3%	-	451.1		-13.5	624.6	415.8	-19.6	339.3	-77.5	-16	148.8
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-	-342.4	-250	-402.4	-200	-350.1	-150.1	-200		134.9
CommonStockIssuance_A Common Stock Issuance Ann.	-	-	-	-	-	-	-	-			134.9
CommonStockPayments_A Common Stock Payments Ann.	-	-	-342.4	-250	-402.4	-200	-350.1	-150.1	-200	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-215.8	-	-	-76.2	-0.4	-	-0.3	-	-	-	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	-16.5%	-1.6%	136.4	115.9	118.4	234.7	119.2	148.2	120.7	58.4	169.2	66.8	43.3
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-43.7%	-5.6%	20.6	-2.5	-116.3	115.5	-29	27.5	62.2	-110.8	102	23.5	-18.1
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-0.9%	-0.8%	115.9	118.4	234.7	119.2	148.2	120.7	58.4	169.2	67.3	43.3	61.4
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	102.5%	267.8%	134.6	80.6	31.8	16.2	-	0.2	0.2	0.2	3	1.4	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	23.2%	11.9%	11.4	10.6	11.4	6.1	3.3	6.5	9	16.9	20.3	3.9	3.8
CapitalExpenditure_A Capex Ann.	-	-	-294.7	-10.7	-15.3	-4.8	-1.5	-2.5	-4	-4.7	-1.4	-3.1	-2.4
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-	-	-	-	-	-	-			134.9
IssuanceOfDebt_A Issuance Of Debt Ann.	11.1%	-	1,470			1,072	784.9		447.4			203
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-1,018.9		-13.5	-447.5	-369.1	-19.6	-108.1	-77.5	-16	-54.3	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-342.4	-250	-402.4	-200	-350.1	-150.1	-200	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	14.9%	46.4%	356.8	468.4	373.3	235.3	298	53	-89.5	-54.2	132.7	-53.5	-39.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

36%

2Y CAGR

29.5%

3Y CAGR

39.5%

5Y CAGR

63.7%

Cash from Operating Activity Annual growth is lower than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

80.37% Gain from 52W Low

Halozyme Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Halozyme Therapeutics Inc - Forecaster

Forecaster Analyst Estimates for Halozyme Therapeutics Inc share price target, revenues, EPS, net income and more

Halozyme Therapeutics Inc - Earnings Report - Quarterly Results

Halozyme Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Halozyme Therapeutics Inc Jun-2026 Quarterly Revenue is $481 Million which is growth of 47.7% YoY.

Quarterly Net Profit Halozyme Therapeutics Inc Jun-2026 Quarterly Net Profit is $230 Million which is growth of 39.2% YoY.

Halozyme Therapeutics Inc - Competitors/Peers

Halozyme Therapeutics Inc competitor comparison and performance snapshot within industry

Halozyme Therapeutics Inc - Earnings Report - Annual Results

Halozyme Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Halozyme Therapeutics Inc Dec-2025 Annual Revenue is $1,397 Million which is growth of 37.6% YoY.

Annual Net Profit Halozyme Therapeutics Inc Dec-2025 Annual Net Profit is $317 Million which is growth of -28.6% YoY.

Halozyme Therapeutics Inc - Balance Sheet

Halozyme Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Halozyme Therapeutics Inc Dec-2025 Total Shareholders Fund is $49 Million which is growth of -86.6% YoY.

Total Assets Halozyme Therapeutics Inc Dec-2025 Total Assets is $2,525 Million which is growth of 22.4% YoY.

Halozyme Therapeutics Inc - Ratios

Halozyme Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Halozyme Therapeutics Inc Book Value Per Share is $1 which is growth of -57.2% YoY.

ROE Halozyme Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Halozyme Therapeutics Inc - Cash Flow

Halozyme Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Halozyme Therapeutics Inc Dec-2025 Cash From Operating Activity is $652 Million which is growth of 36.0% YoY.

Net Cash Flow Halozyme Therapeutics Inc Dec-2025 Net Cash Flow is $21 Million which is growth of 916.3% YoY.